Wells Fargo Initiates Coverage of Avadel Pharmaceuticals (AVDL) with Equal-Weight Recommendation
Wells Fargo has initiated coverage of Avadel Pharmaceuticals (AVDL) with an "Equal-Weight" rating. This new coverage provides investors with an analyst's perspective on the company's stock performance and future outlook. The "Equal-Weight" recommendation suggests that Wells Fargo expects Avadel's stock to perform in line with the broader market.
Wells Fargo Initiates Coverage of Avadel Pharmaceuticals (AVDL) with Equal-Weight Recommendation
Wells Fargo has initiated coverage of Avadel Pharmaceuticals (AVDL) with an "Equal-Weight" rating. This new coverage suggests a neutral outlook on the company's stock performance from the analytical firm. Investors will likely be watching for Avadel's market movements following this initiation.
Leerink Partners Downgrades Avadel Pharmaceuticals (AVDL)
This article reports that Leerink Partners has downgraded Avadel Pharmaceuticals' (AVDL) stock. More details are needed to understand the reasons behind the downgrade and its potential implications for the company and its investors.
EBITDA per share of Avadel Pharmaceuticals plc – LS:A2DJ5B
This page from TradingView provides financial data for Avadel Pharmaceuticals plc (LS:A2DJ5B), specifically focusing on its EBITDA per share. It appears to be a financial overview page allowing users to access various data points for the company.
Avadel (AVDL) Soars to 10-Year High on Brewing Bidding War
Avadel Pharmaceuticals' stock (AVDL) surged over 13% to a 10-year high following news of a potential bidding war for the company, as reported by The Fly. This interest arose after HC Wainwright initiated coverage with a "Buy" rating and a hefty price target, suggesting the company could be an attractive acquisition target due to its sole commercial product, Lumryz. The FDA approval and launch of Lumryz, a once-nightly narcolepsy treatment, and the company's strong financial position with sufficient cash to fund operations, make it appealing to larger pharmaceutical firms.
Avadel Pharmaceuticals Announced Transfer or Voluntary Withdrawal of Listing
Avadel Pharmaceuticals (AVDL) has requested Nasdaq to halt trading and delist its shares following its acquisition by Alkermes. The company intends to file a Form 25 to delist, and subsequently, Alkermes and Avadel will file a Form 15 to deregister shares and suspend Exchange Act reporting obligations. This action was initiated on February 11, 2026, with the original SEC filing on February 12, 2026.
[15-12G] AVADEL PHARMACEUTICALS PLC SEC Filing
Avadel Pharmaceuticals PLC (AVDL) has filed Form 15-12G with the SEC, certifying the termination of its registration under Section 12(g) of the Securities Exchange Act of 1934 and the suspension of its duty to file reports. This filing indicates that the company now has only one holder of record. The move follows Alkermes plc's acquisition of Avadel Pharmaceuticals plc, which completed on February 12, 2026.
[EFFECT] AVADEL PHARMACEUTICALS PLC SEC Filing
This SEC filing concerns Avadel Pharmaceuticals PLC with the ticker AVDL. It is a Notice of Effectiveness filing with an effectiveness date of February 13, 2026. The filing indicates a neutral impact and sentiment according to Rhea-AI.
How Avadel Pharmaceuticals Plc (AVDL) Affects Rotational Strategy Timing
This article from Stock Traders Daily discusses how Avadel Pharmaceuticals Plc (AVDL) influences rotational strategy timing, based on analysis from their predictive AI models. It outlines institutional trading strategies like Position Trading, Momentum Breakout, and Risk Hedging, though specific entry/target/stop loss zones are noted as "N/A." The piece emphasizes multi-timeframe signal analysis and encourages users to access real-time signals and personalized alerts by creating a free account.
Weiss Asset reports 11.1M Avadel (NASDAQ: AVDL) shares on Form 3
Weiss Asset Management LP and Andrew Weiss have disclosed an initial beneficial ownership of 11.1 million ordinary shares in Avadel Pharmaceuticals (NASDAQ: AVDL) via a Form 3 filing. These shares are held indirectly through two private investment funds managed by Weiss Asset Management. The reporting parties disclaim beneficial ownership except for their pecuniary interest in these holdings.
Two Seas Capital reports 0% ownership in Avadel Pharmaceuticals (AVDL)
Two Seas Capital LP, Two Seas Capital GP LLC, and Sina Toussi have filed an amended Schedule 13G/A, reporting 0% beneficial ownership in Avadel Pharmaceuticals (AVDL) as of December 31, 2025. This filing indicates that the reporting persons no longer hold ordinary shares of Avadel Pharmaceuticals and have no voting or dispositive power over them. The previous holdings were managed by Two Seas Capital LP for Two Seas Global (Master) Fund LP, but the group now confirms ownership of less than 5% of the class.
Janus Henderson (AVDL) reports 1.9% beneficial stake in Avadel
Janus Henderson Group plc has reported a beneficial ownership of 1,823,865 ordinary shares of Avadel Pharmaceuticals plc (AVDL), which represents 1.9% of the share class as of December 31, 2025. These shares are held across various asset manager subsidiaries in managed client portfolios. Janus Henderson disclaims economic ownership, with all benefits belonging to the underlying managed portfolios, and no single managed portfolio holds more than 5% of Avadel's shares.
[EFFECT] AVADEL PHARMACEUTICALS PLC SEC Filing
This article announces an SEC Filing (Form EFFECT) by AVADEL PHARMACEUTICALS PLC (AVDL) which was declared effective on February 13, 2026. The filing indicates a neutral impact and sentiment. It also provides recent news and SEC filings for Avadel Pharmaceuticals, highlighting its acquisition by Alkermes plc.
Ireland's Alkermes plc buys Avadel Pharmaceuticals plc
Alkermes plc has completed its $2.3 billion acquisition of Avadel Pharmaceuticals plc, adding the FDA-approved narcolepsy drug LUMRYZ to its commercial portfolio. This strategic move aims to accelerate Alkermes' entry into the sleep medicine market, strengthen its pipeline, and enhance commercial capabilities, with the deal expected to be accretive by 2026. The acquisition was financed through a combination of cash and new debt, and Alkermes plans to provide updated financial expectations for the combined entity in February 2026.
[EFFECT] AVADEL PHARMACEUTICALS PLC SEC Filing
This article announces an SEC Filing of form EFFECT for Avadel Pharmaceuticals PLC (AVDL), dated February 13, 2026. The filing has a neutral impact and sentiment according to Rhea-AI. It also provides recent news and other SEC filings related to Avadel Pharmaceuticals.
Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc
This article details an 8.3 Form disclosure from The Vanguard Group, Inc. regarding Avadel Pharmaceuticals plc. The disclosure outlines Vanguard's interests and short positions in Avadel's ordinary shares, totaling 5,396,577 shares or 5.54%. It also reports specific purchase and sale dealings in Avadel Pharmaceuticals plc shares that occurred on February 10, 2026.
Alkermes Completes Acquisition of Avadel Pharmaceuticals, Adding LUMRYZ to Portfolio
Alkermes has completed its acquisition of Avadel Pharmaceuticals, integrating the FDA-approved narcolepsy treatment LUMRYZ into its commercial portfolio and strengthening its presence in the sleep medicine market. This deal, finalized on February 12, 2026, is expected to be accretive in 2026 and includes the pipeline candidate valiloxybate, enhancing Alkermes' capabilities in treating central disorders of hypersomnolence. Alkermes financed the acquisition with cash and term loans, planning to rapidly pay down debt using business cash flows.
Alkermes PLC has successfully completed the acquisition of Avadel Pharmaceuticals plc.
Alkermes PLC has finalized its acquisition of Avadel Pharmaceuticals plc, a strategic move aimed at rapidly entering the sleep medication market. This acquisition is expected to bolster Alkermes' presence in the specialty pharmaceutical sector and leverage Avadel's expertise in sleep disorder treatments for future growth.
RFG Advisory LLC Acquires New Holdings in Avadel Pharmaceuticals PLC. $AVDL
RFG Advisory LLC has acquired a new position in Avadel Pharmaceuticals PLC (NASDAQ: AVDL), purchasing 73,944 shares valued at approximately $1.13 million. This comes as institutional investors and hedge funds significantly increase their stakes, with total institutional ownership reaching 69.19%. Despite this institutional accumulation, analyst sentiment has cooled, leading to multiple downgrades and a consensus "Hold" rating with a $20.00 price target, while the stock currently trades around $21.64.
(AVDL) and the Role of Price-Sensitive Allocations
Avadel Pharmaceuticals Plc (NASDAQ: AVDL) is currently exhibiting a neutral near and mid-term outlook with a long-term positive bias, according to AI analysis. The analysis identifies a mid-channel oscillation pattern and presents three distinct trading strategies (Position, Momentum Breakout, and Risk Hedging) tailored for different risk profiles. Key findings include a 29.7:1 risk-reward short setup targeting a 9.2% downside, with specific entry, target, and stop-loss levels provided.
Irish court clears Alkermes buyout; Avadel stock trading ends Feb. 11
The Irish High Court has sanctioned the scheme of arrangement for Alkermes to acquire all ordinary shares of Avadel Pharmaceuticals without modification. The scheme is expected to take effect on February 12, 2026, with February 11, 2026, being the last day for Avadel shares to trade on Nasdaq, followed by a trading halt at 8:00 p.m. U.S. Eastern Time. The completion of the transaction still depends on the delivery of the Court Order to the Registrar of Companies.
Avadel Pharmaceuticals plc Announces High Court Approval of Scheme of Arrangement for Acquisition by Alkermes plc
Avadel Pharmaceuticals plc announced that the Irish High Court has approved its scheme of arrangement for acquisition by Alkermes plc. This acquisition, involving all of Avadel's ordinary shares, is expected to take effect on February 12, 2026, contingent on the Court Order's processing. As a result, trading of Avadel shares on Nasdaq is anticipated to cease after February 11, 2026.
Penserra Capital Management LLC Buys New Holdings in Avadel Pharmaceuticals PLC. $AVDL
Penserra Capital Management LLC has acquired 126,131 shares of Avadel Pharmaceuticals PLC (NASDAQ:AVDL) for approximately $1.93 million, representing a new holding and about 0.13% ownership. Hedge funds and institutional investors collectively own 69.19% of the stock. Analysts have a "Hold" consensus rating with an average price target of $18.86, despite recent downgrades from several firms and an upgrade from Wells Fargo & Company.
Goldman Sachs (EPT) - Form 38.5b- AVADEL PHARMACEUTICALS PLC
Goldman Sachs International has filed a Form 38.5(b) disclosure with the Irish Takeover Panel regarding dealings in Avadel Pharmaceuticals PLC ordinary shares. The filing details Goldman Sachs's interests and short positions, showing a long position of 3,396 shares (0.00%) and no short position following transactions on February 4, 2026. The firm acted as an advisor to the offeree, Avadel Pharmaceuticals PLC.
Form 8.3 -Avadel Pharmaceuticals plc
This document is a Form 8.3 disclosure filed by State Street Global Advisors & Affiliates regarding their dealings in Avadel Pharmaceuticals plc. It details the firm's interests and short positions, showing ownership of 2,353,996 ordinary shares representing 2.41675% of the company's relevant securities. The disclosure also reports a purchase of 2,434 shares at a price of 21.57 on February 4th, 2026, and confirms no other derivative or options transactions.
Avadel Pharmaceuticals PLC. (NASDAQ:AVDL) Sees Large Increase in Short Interest
Avadel Pharmaceuticals (NASDAQ:AVDL) saw a 32.1% increase in short interest as of January 15th, reaching 3,607,258 shares, representing about 3.9% of the company's stock. Despite increased bearish positioning, institutional investors own 69.19% of the company, with several large funds significantly increasing their stakes. Analysts currently have a "Hold" consensus rating with an average price target of $18.86, while the stock traded around $21.55 on Monday.
Bank of America discloses 2.39% stake in Avadel Pharmaceuticals By Investing.com
Bank of America has disclosed a 2.39% stake in Avadel Pharmaceuticals plc, as reported in a recent regulatory filing. This stake includes direct ownership and cash-settled derivatives, along with details of recent trading activities by the bank in Avadel shares. Avadel Pharmaceuticals is a Nasdaq-listed company specializing in central nervous system disorder medications.
Responsive Playbooks and the AVDL Inflection
This article provides an analysis of Avadel Pharmaceuticals Plc (NASDAQ: AVDL), noting a neutral near and mid-term outlook but a positive long-term bias. It highlights an exceptional 37.8:1 risk-reward short setup and offers three distinct AI-generated trading strategies for different risk profiles and holding periods, including entry zones, targets, and stop losses. The analysis also includes multi-timeframe signal analysis and encourages users to access real-time signals and personalized alerts.
Avadel Pharmaceuticals PLC. (NASDAQ:AVDL) Receives Consensus Recommendation of "Hold" from Analysts
Avadel Pharmaceuticals PLC (NASDAQ:AVDL) has received a consensus "Hold" rating from analysts, with an average 12-month price target of $18.86. Despite a 55% year-over-year revenue increase, the company missed its recent quarterly EPS and revenue expectations. Institutional investors and hedge funds hold a significant portion of the stock, with several major firms increasing their stakes.
Alkermes stock price target raised to $47 from $46 at UBS on Avadel deal
UBS has increased its price target for Alkermes (NASDAQ:ALKS) to $47 from $46, maintaining a Buy rating, due to the anticipated acquisition of Avadel Pharmaceuticals. This acquisition is expected to boost Alkermes' EBITDA growth and strengthen its Sleep franchise, along with upcoming clinical trial results for Lumryz and alixorexton. Alkermes has also received Breakthrough Therapy designation for alixorexton and raised its offer for Avadel to $21.00 per share, plus a CVR.
Form 8.3 -Avadel Pharmaceuticals plc
This Form 8.3 filing details disclosures under Rule 8.3 of the Irish Takeover Panel Act by State Street Global Advisors & Affiliates regarding Avadel Pharmaceuticals plc. It reports an interest of 2,333,492 ordinary shares, representing 2.39570% of the company, following purchases made on January 26, 2026. The document outlines dealings in Avadel Pharmaceuticals plc shares, including specific purchase transactions, and confirms no other options or derivative transactions.
Avadel Pharmaceuticals Announces Court Hearing for Acquisition
Avadel Pharmaceuticals has announced a court hearing relevant to its acquisition by Alkermes, scheduled for February 10, 2026, in Ireland. Alkermes plans to acquire all Avadel shares, with the acquisition expected to finalize after court sanction. Interested parties must provide notification by February 5, 2026.
Avadel Pharmaceuticals appoints Susan Rodriguez as COO
Avadel Pharmaceuticals has announced the appointment of Susan Rodriguez as its new Chief Operating Officer (COO). This strategic hire is expected to strengthen the company's operational leadership as it continues to develop and commercialize its pharmaceutical products. Rodriguez brings extensive experience to her new role, which will be crucial for Avadel's ongoing growth and market expansion.
State Street Increases Stake in Avadel Pharmaceuticals by 2.39%
State Street Global Advisors and affiliates have increased their stake in Avadel Pharmaceuticals by 2.39%, purchasing 29,196 shares at $21.48 each. This move reflects confidence in Avadel's future growth and complies with Irish Takeover Panel regulations. Analysts, however, have varied price targets for AVDL, with the average 1-year target at $20.29.
BlackRock discloses 6.94% stake in Avadel Pharmaceuticals By Investing.com
BlackRock, Inc. has publicly announced a 6.94% ownership stake in Avadel Pharmaceuticals plc, as revealed in a regulatory filing made through Ireland’s Takeover Panel. This disclosure indicates BlackRock holds over 6.8 million ordinary shares in the pharmaceutical company and minimal short positions. The investment giant also made recent additional purchases of Avadel shares on January 15, 2026.
BlackRock discloses 6.94% stake in Avadel Pharmaceuticals
BlackRock, an investment giant, has revealed a 6.94% ownership stake in Avadel Pharmaceuticals plc, as per a recent regulatory filing in Ireland. The disclosure indicates BlackRock holds over 6.8 million ordinary shares and recently acquired additional shares on January 15, 2026. This significant stake in the pharmaceutical company was reported under Irish Takeover Panel regulations.
Janus Henderson discloses 1.87% stake in Avadel Pharmaceuticals
Investment firm Janus Henderson Group has disclosed a 1.87% stake in Avadel Pharmaceuticals plc, totaling 1,824,080 ordinary shares as of January 15, 2026. This disclosure was made under Irish Takeover Panel rules and includes recent share transactions. Avadel Pharmaceuticals is an Irish biopharmaceutical company focusing on central nervous system disorders.
Bank of America discloses 1.3% stake in Avadel Pharmaceuticals
Bank of America Corporation has disclosed a 1.3% stake in Avadel Pharmaceuticals plc, as per a regulatory filing with the Irish Takeover Panel. This includes both directly owned shares and interests through cash-settled derivatives, along with significant short positions. The disclosure follows transactions made on January 15, and is mandated under Irish takeover rules for entities holding 1% or more in potentially involved companies.
Morgan Stanley discloses trading activity in Avadel Pharmaceuticals shares
Morgan Stanley & Co. LLC reported its trading activities in Avadel Pharmaceuticals plc (NASDAQ:AVDL) shares, purchasing 238,091 ordinary shares and selling 238,083 shares on January 15, 2026, at prices between $21.48 and $21.59. The disclosure was made under Irish Takeover Panel Act Rule 38.5(a), identifying Morgan Stanley as an exempt principal trader connected to an unspecified offer relating to Avadel Pharmaceuticals. The biopharmaceutical company focuses on developing products for sleep disorders and CNS conditions.
Bank of America discloses 1.32% stake in Avadel Pharmaceuticals By Investing.com
Bank of America has revealed a 1.32% stake in Avadel Pharmaceuticals plc, holding 1,286,976 shares, including ordinary shares and cash-settled derivatives. The disclosure was made due to regulatory requirements for holdings exceeding 1% in companies potentially involved in takeover situations, although no active takeover offer for Avadel was indicated. Bank of America also reported transactions on January 14, including purchases and sales of ordinary shares, and changes in cash-settled derivative positions.
Bank of America discloses 1.32% stake in Avadel Pharmaceuticals By Investing.com
Bank of America Corporation has revealed a 1.32% stake in Avadel Pharmaceuticals plc, as per a recent regulatory filing. This includes ownership of 1,286,976 shares, comprising ordinary shares and cash-settled derivatives, along with short positions. The disclosure details transactions from January 14 and adheres to regulatory requirements for significant holdings in potential takeover scenarios.
Janus Henderson discloses 1.87% stake in Avadel Pharmaceuticals
Investment firm Janus Henderson Group plc has revealed a 1.87% stake in Avadel Pharmaceuticals plc through a regulatory filing. The disclosure, made under Irish takeover regulations, shows Janus Henderson owning and controlling 1,823,623 ordinary shares of Avadel. The filing also detailed recent trading activity, including purchases and sales of Avadel shares on January 14.
FIL Limited discloses 3.14% stake in Avadel Pharmaceuticals By Investing.com
FIL Limited and its subsidiaries have revealed a 3.14% ownership stake in Avadel Pharmaceuticals PLC, an Irish biopharmaceutical company. This disclosure, made public under Irish Takeover Panel rules, indicates that FIL Limited holds over 3 million ordinary shares in Avadel Pharmaceuticals as of January 13, 2026, and also details a recent purchase of 80,000 shares. The filing notes that FMR LLC also has interests in the company and clarifies that there are no indemnity or option arrangements related to these securities.
BlackRock discloses 6.74% stake in Avadel Pharmaceuticals
BlackRock, an investment management firm, has disclosed a 6.74% stake in Avadel Pharmaceuticals plc, totaling 6,617,364 ordinary shares as of January 9, 2026. The disclosure was made under Irish Takeover Panel rules and also noted a minimal short position and recent trading activities by BlackRock. Avadel Pharmaceuticals, which focuses on central nervous system disorders, has not commented on BlackRock's position.
Morgan Stanley discloses trading in Avadel Pharmaceuticals shares By Investing.com
Morgan Stanley & Co. LLC reported its trading activity in Avadel Pharmaceuticals plc (NASDAQ: AVDL) shares to the Irish Takeover Panel. The investment bank, acting as an exempt principal trader, purchased 240,438 ordinary shares and sold 240,394 shares on January 9, 2026, with prices ranging from $21.46 to $21.53. This disclosure was made in compliance with Irish takeover regulations due to Morgan Stanley's connection to Avadel Pharmaceuticals in relation to a potential transaction.
Morgan Stanley discloses dealings in Avadel Pharmaceuticals shares By Investing.com
Morgan Stanley & Co. International plc reported that it bought and sold 21 ordinary shares of Avadel Pharmaceuticals plc (NASDAQ:AVDL) at $21.50 per share on January 9, 2026. This disclosure was made in accordance with Irish Takeover Panel regulations, identifying Morgan Stanley as connected to Avadel Pharmaceuticals. No other complex financial arrangements were reported in connection with these transactions.
BlackRock discloses 6.3% stake in Avadel Pharmaceuticals
BlackRock, Inc. has publicly disclosed a 6.3% ownership stake in Avadel Pharmaceuticals plc, as revealed in a regulatory filing made through Ireland’s Takeover Panel. This stake, amounting to 6,187,320 ordinary shares, was held as of January 8, 2026, and also included a minimal short position. The disclosure was made under regulatory requirements for entities with significant interests in companies potentially involved in takeover situations.
Goldman Sachs (EPT) - Form (38.5b)AVADEL PHARMACEUTICALS PLC
This article reports a disclosure by Goldman Sachs International under Irish Takeover Panel Rules, detailing dealings in AVADEL PHARMACEUTICALS PLC shares. As an exempt principal trader connected to the offeree, Goldman Sachs reported both long and short positions for USD 0.01 ordinary shares, following transactions on January 7, 2026. The firm disclosed various purchases and sales, including borrow full return and borrow new transactions, affecting 4,524 relevant securities.
Do Options Traders Know Something About Avadel Pharmaceuticals Stock We Don't?
Options traders are showing heightened interest in Avadel Pharmaceuticals (AVDL) with a significant implied volatility in the Jan 16, 2026 $25.00 Put options, indicating expectations of a notable price movement. Despite an increase in the Zacks Consensus Estimate for the current quarter, analysts currently rate AVDL as a Zacks Rank #3 (Hold). This high implied volatility could suggest an emerging trading opportunity for options traders, particularly those who sell premium.
Morgan Stanley discloses dealings in Avadel Pharmaceuticals shares
Morgan Stanley Capital Services LLC disclosed its trading activity in Avadel Pharmaceuticals plc (NASDAQ:AVDL) on January 8, 2026, including the purchase of 22,990 ordinary shares and sale of 111 ordinary shares. The firm also increased its short positions in Avadel through cash-settled derivative transactions involving 22,417 reference securities. This disclosure was made in compliance with Irish Takeover Panel requirements, as Morgan Stanley acts as a connected exempt principal trader.
